Gilde Healthcare Partners

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Founded in 2016 and headquartered in Utrecht, the Netherlands, Lava Therapeutics is a biotechnology company specializing in the development of proprietary Vγ9Vδ2 T-cell engagers for immune oncology. Its platform focuses on creating bispecific antibodies to engage gamma-delta T cells for treating hematological and solid cancers.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Founded in 2016 and headquartered in Utrecht, the Netherlands, Lava Therapeutics is a biotechnology company specializing in the development of proprietary Vγ9Vδ2 T-cell engagers for immune oncology. Its platform focuses on creating bispecific antibodies to engage gamma-delta T cells for treating hematological and solid cancers.

Performation Healthcare Intelligence is a prominent provider of healthcare-specific business intelligence solutions in the Netherlands. The company specializes in software, data analysis, and advisory services aimed at helping healthcare organizations monitor costs, processes, and quality. With a dedicated team of over a hundred consultants and business intelligence experts, Performation enables its clients to make informed decisions that enhance the delivery of effective and high-quality care. By addressing healthcare-wide information challenges and integrating data into actionable insights, the company supports its clients in optimizing their operations and improving patient outcomes.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

NIZO food research BV is an independent contract research organization based in Ede, the Netherlands, with additional offices in the United States, France, and Japan. Founded in 1948, NIZO specializes in providing research and innovation services to the dairy, food and beverage, ingredients, and biotech industries. The company focuses on developing new flavors and textures, utilizing advanced technologies to enhance food products while addressing sustainability, cost-effectiveness, and speed to market. NIZO's offerings include analysis, contract research, production services, webinars, white papers, training programs, and pre-competitive research. The company also operates a food-grade processing plant to bring innovative food technologies to life.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Viroclinics Biosciences is a prominent contract research and clinical laboratory service provider specializing in virology. The company focuses on diagnostic and preclinical studies, as well as drug development aimed at preventing and treating viral infections, particularly respiratory viruses like influenza. Viroclinics offers an extensive range of virology services that support both new drug development programs and post-marketing surveillance of existing drugs and vaccines. Their capabilities include traditional virology assays and advanced deep sequencing protocols applicable to a wide variety of viruses. Operating BSL2 and BSL3 laboratories, Viroclinics conducts analyses in compliance with international ISO 15189 accreditation standards. The company collaborates closely with the Erasmus MC Viroscience lab, enhancing its expertise in developing antivirals and vaccines while serving the biopharmaceutical community with tailored models for preclinical drug testing and expert guidance.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Pharmaline is an innovative semi-industrial compounding pharmacy located in Oldenzaal, Netherlands. Established in 2009 with 30 employees, the company has grown to over 140 staff members, all operating under the latest Good Manufacturing Practice (GMP) guidelines. Pharmaline provides a comprehensive range of pharmaceutical solutions, serving approximately 700 pharmacists across the Netherlands. The company focuses on standardization and rationalization to enhance the quality of care while reducing healthcare costs. Its offerings include both stock preparations and ad hoc preparations tailored to patient needs, encompassing creams, ointments, tablets, capsules, drops, liquids, suspensions, and injectables. Pharmaline aims to be a one-stop solution for pharmacy preparations, ensuring that pharmacists have easy access to necessary products. The company employs experienced pharmacists who provide expert advice on various aspects of pharmacotherapy, production engineering, application engineering, and legislation, all supported by modern equipment.

Fysius Rugexperts is a leading chain of clinics in the Netherlands that specializes in treating lower-back and related pains. Utilizing the latest scientific insights, Fysius employs advanced treatment methods and aids, including the OriGENE device, to address chronic back and spinal pain. With a strong focus on patient care, the clinic treats over 10,000 patients annually, making it the largest and most specialized facility for back pain in the country. Fysius aims to help individuals maintain their health and fitness by effectively addressing spine-related issues.

ProFibrix B.V. is a biotechnology company focused on developing and marketing innovative products for the hemostasis and regenerative medicine sectors. Founded in 2004, the company specializes in Fibrocaps, a dry powder topical hemostat and tissue sealant designed to effectively control acute and severe bleeding during surgical procedures or due to traumatic injuries. Fibrocaps is formulated from a blend of fibrinogen and thrombin, two key proteins vital for blood clotting and tissue repair. Additionally, ProFibrix offers a sterilized single-use delivery device that facilitates the application of Fibrocaps to targeted areas, minimizing the need to manipulate the wound in a surgical setting. The company's products leverage human fibrinogen, a natural blood protein, to enhance hemostatic efficacy and promote healing.

VerzuimVitaal B.V. is a Dutch company that specializes in providing occupational health services aimed at managing employee absenteeism. Founded in 2011 and located in Woerden, the Netherlands, the company focuses on enhancing the vitality of organizations and their employees to reduce absenteeism costs. In addition to promoting employee wellness, VerzuimVitaal oversees the management of sick leave and the reintegration process for employees returning to work.

ProFibrix B.V. is a biotechnology company focused on developing and marketing innovative products for the hemostasis and regenerative medicine sectors. Founded in 2004, the company specializes in Fibrocaps, a dry powder topical hemostat and tissue sealant designed to effectively control acute and severe bleeding during surgical procedures or due to traumatic injuries. Fibrocaps is formulated from a blend of fibrinogen and thrombin, two key proteins vital for blood clotting and tissue repair. Additionally, ProFibrix offers a sterilized single-use delivery device that facilitates the application of Fibrocaps to targeted areas, minimizing the need to manipulate the wound in a surgical setting. The company's products leverage human fibrinogen, a natural blood protein, to enhance hemostatic efficacy and promote healing.

Galapagos NV is a clinical-stage biotechnology company based in Mechelen, Belgium, that focuses on discovering, developing, and commercializing small molecule medicines. The company’s clinical programs include filgotinib, a JAK1 inhibitor undergoing trials for multiple conditions such as rheumatoid arthritis and Crohn’s disease, as well as GLPG1690, an autotaxin inhibitor in trials for idiopathic pulmonary fibrosis and systemic sclerosis. Additionally, Galapagos is developing GLPG1205, a GPR84 inhibitor for idiopathic pulmonary fibrosis, and GLPG1972 for osteoarthritis. The company also explores Toledo molecules for inflammation. Galapagos has established collaborations with several pharmaceutical companies, including Gilead Sciences and AbbVie. Founded in 1999, Galapagos aims to address diseases with high unmet medical needs and improve patient outcomes globally.